Filing Flows › Evommune (EVMN) › Stock forecast & fair value
Evommune (EVMN) stock forecast and price target
Evommune (EVMN) trades at $6.65. 9 analysts' median price target is $22.00 (+231%), from $8.00 to $30.00.
Evommune's latest quarter
Evommune, Q3 2025: revenue $10.0M, operating margin -133.3%, net loss $12.5M, operating cash flow −$9.6M. The chart follows the revenue to costs, profit and cash.
Questions
What is the price target for EVMN stock?
The median of 9 analysts' 12-month targets is $22.00, +231% from $6.65; the range is $8.00 to $30.00. The average rating is buy.
Does Evommune usually beat earnings estimates?
It beat the consensus EPS estimate in 33% of the quarters on record.
Is EVMN stock a buy?
Filing Flows does not give advice. It shows what analysts expect, what each valuation method implies and the figures behind them, read from SEC filings, so you can judge for yourself.
Updated Nov 8, 2026. Read automatically from SEC filings and public data; errors are possible. Not investment advice.